Genentech Phase III Combo Cuts PFS Risk 44%
Genentech's Phase III evERA trial showed giredestrant plus everolimus improved progression-free survival (PFS) by 44% versus standard endocrine therapy plus everolimus in the intent-to-treat population. The FDA has accepted new drug applications for the combination, with decisions expected by November 30 and December 18, 2026.
38 in the ESR1-mut group. The FDA has accepted the NDAs, and decisions are expected by Nov 30 and Dec 18, 2026.